Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1987 1
1988 1
1989 4
1990 1
1991 4
1992 4
1993 4
1994 1
1995 2
1996 2
1998 1
2000 1
2002 1
2017 1
2018 3
2019 3
2020 5
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Vranckx P, et al. Among authors: zierhut w. Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3. Lancet. 2019. PMID: 31492505 Clinical Trial.
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR, Weiss TW, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Waltenberger J, Steffel J, Levy P, Bakhai A, Zierhut W, Laeis P, Manu MC, Reimitz PE, De Caterina R, Kirchhof P. de Groot JR, et al. Among authors: zierhut w. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f30-f39. doi: 10.1093/ehjcvp/pvaa079. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32790837 Free PMC article.
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Agnelli G, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Cohen AT; ETNA-VTE-Europe investigators. Agnelli G, et al. Among authors: zierhut w. Thromb Res. 2020 Dec;196:297-304. doi: 10.1016/j.thromres.2020.09.001. Epub 2020 Sep 12. Thromb Res. 2020. PMID: 32950897
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
Cohen AT, Hoffmann U, Hainaut P, Gaine S, Ay C, Coppens M, Schindewolf M, Jimenez D, Brüggenjürgen B, Levy P, Laeis P, Fronk EM, Zierhut W, Malzer T, Manu MC, Reimitz PE, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: zierhut w. Eur J Intern Med. 2020 Dec;82:48-55. doi: 10.1016/j.ejim.2020.08.014. Epub 2020 Aug 18. Eur J Intern Med. 2020. PMID: 32826158
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EM, Giugliano RP. Nicolau AM, et al. Among authors: zierhut w. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):167-175. doi: 10.1093/ehjcvp/pvz061. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31687762
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen J, Goette A. Vranckx P, et al. Among authors: zierhut w. Eur Heart J. 2020 Dec 14;41(47):4497-4504. doi: 10.1093/eurheartj/ehaa617. Eur Heart J. 2020. PMID: 32860041 Free PMC article. Clinical Trial.
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Cohen AT, Ay C, Hainaut P, Décousus H, Hoffmann U, Gaine S, Coppens M, da Silva PM, Jimenez D, Amann-Vesti B, Brüggenjürgen B, Levy P, Bastida JL, Vicaut E, Laeis P, Fronk EM, Zierhut W, Malzer T, Bramlage P, Agnelli G; ETNA-VTE-Europe investigators. Cohen AT, et al. Among authors: zierhut w. Thromb J. 2018 May 31;16:18. doi: 10.1186/s12959-018-0173-5. eCollection 2018. Thromb J. 2018. PMID: 29855634 Free PMC article.
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: zierhut w. BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x. BMC Cardiovasc Disord. 2019. PMID: 31299906 Free PMC article.
41 results